Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

Drug Pricing 'Deeper Dive' Planned By Senate Cmte. As Industry Avoids First Blood

Hearings in July and the fall will follow, but if the first session was any indication, industry doesn't have anything to worry about.

Policy Pricing Debate Legislation

Latest From Pricing Debate

Bayer's Weinand On Pricing, Payers And Pipelines

Bayer's pharma president and board member Dieter Weinand talks to Scrip about the importance of big picture thinking when weighing the value of innovative drugs to healthcare systems, the revolutionary potential of big data and how "transparency and open dialogue will further enhance the understanding of our business."

Scrip 100 Pricing Debate

340B Penny Pricing, Civil Monetary Penalty Revisions On Deck In Proposed Rule

Proposed rule will revisit controversial provisions in the January 340B final rule to address manufacturer concerns about the US discount program.

Pricing Strategies Market Access

Argentina Rejects Key Sofosbuvir Patent Application

Argentina’s patent office, INPI, has rejected an application for a key patent relating to Gilead’s hepatitis C drug Sovaldi (sofosbuvir).

South America Argentina

Drug Pricing: US House, Senate, Taking Bicameral Go-Slow Approach

Energy & Commerce Health Subcommittee hearing on drug pricing and the supply chain begins information gathering process, leadership says. Subcommittee Chair Burgess urges stakeholders to seek consensus on market-based solutions or else.

Pricing Debate Policy & Regulation

Drug Pricing: US Senate Hearings Conclude With No Clear View On Legislation

Measures that would increase financial transparency and empower federal government to negotiate drug prices highlighted by National Academies representative who discussed recent report on drug affordability, but former Congressional Budget Office Director Holtz-Eakin warns Senate HELP Committee against taking measures that merely shift costs from one party to another.

Pricing Debate Pharmacy Benefit Management

PhRMA Sues To Block 'Unprecedented' California Price Reporting Law

Ban on WAC price increases violates Commerce Clause and reporting requirement violates First Amendment, PhRMA contends; complaint says state officials have not clarified whether law is retroactive.

BioPharmaceutical Policy

Some Drug Prices Could Drop 40% Under Canada’s Cost Lowering Proposals

The prices of patented medicines overall are expected to go down in Canada under new proposed regulatory amendments.

Pricing Debate Canada

Spark's Hemophilia B Gene Therapy SPK9001 Packs A Punch And Saves Big Bucks

A New England Journal of Medicine publication and editorial highlighted a small study of ten patients in which one infusion of Spark/Pfizer's SPK9001 gene therapy "nearly completely eliminated" the need for factor IX clotting products, saving $200,000 per patient per year.

Clinical Trials Blood & Coagulation Disorders

US Retail Drug Spending Growth Slows Substantially In 2016

Retail drug spending rose just 1.3% in 2016, following growth rates of 8.9% and 12.4% in 2015 and 2014, respectively. Moderating trend is reported just ahead of two congressional hearings on drug pricing.

Pricing Debate Reimbursement
See All
UsernamePublicRestriction

Register